There is no way to fully get rid of herpes simplex virus (HSV) from your body. Once you’re infected, the virus retreats into nerve clusters called sensory ganglia and stays there for life. Antiviral medications can’t reach it in this dormant state, and the virus has evolved mechanisms to evade immune cells that try to clear it. What you can do is reduce outbreaks, shorten healing time, lower the chance of spreading it, and in many cases live with few or no symptoms at all.
Why HSV Can’t Be Eliminated Yet
After a primary infection, HSV travels along nerve fibers and settles into clusters of nerve cells near the spine (for genital herpes) or near the base of the skull (for oral herpes). There, it enters a dormant phase called latency. Your immune system stations specialized T cells around these nerve clusters to keep the virus in check, but the virus has evolved ways to avoid being destroyed by those same immune cells. Antiviral drugs work by blocking the virus from copying itself during active outbreaks, but they have no effect on dormant viral DNA sitting quietly inside your neurons.
This is the core reason no treatment “gets rid of” herpes. The virus isn’t circulating in your blood where drugs or antibodies can easily find it. It’s hiding inside cells your body can’t afford to destroy.
Antiviral Therapy: Episodic vs. Suppressive
Antiviral medications are the most effective tool available for managing HSV. They come in two strategies: episodic therapy, where you take medication at the first sign of an outbreak to shorten it, and suppressive therapy, where you take a lower dose daily to prevent outbreaks from happening in the first place.
For episodic treatment of genital HSV-2, courses are short, typically two to five days depending on the medication and dosing schedule. You start as soon as you notice prodromal symptoms like tingling, itching, or redness. The earlier you begin, the more effective it is. Some regimens are as brief as a single day.
Suppressive therapy is taken every day, whether or not you have symptoms. It’s particularly useful if you experience frequent outbreaks (generally six or more per year) or if you want to reduce the risk of passing HSV to a partner. In a large clinical trial of discordant couples (where one partner had HSV-2 and the other didn’t), daily suppressive therapy cut symptomatic transmission by 75% and reduced overall transmission by about 48%. These are meaningful reductions, though not complete protection.
For genital HSV-1, outbreaks tend to recur far less often than HSV-2, so daily suppressive therapy is usually reserved for people who still get frequent flare-ups.
Asymptomatic Shedding Still Happens
One thing that surprises many people is that HSV can be present on the skin or mucous membranes without any visible sores. This is called asymptomatic shedding, and it’s a major route of transmission. Research from Fred Hutchinson Cancer Center found that people with symptomatic genital HSV-2 shed the virus on about 20% of days, while those who never notice symptoms still shed on roughly 10% of days. Suppressive antiviral therapy reduces shedding, but doesn’t eliminate it entirely. Condoms provide additional protection but don’t cover all potentially affected skin.
Common Outbreak Triggers
The virus reactivates from its dormant state in response to a range of physical and emotional triggers. The most consistently reported ones include psychological stress, illness or immune suppression, UV sun exposure (especially for oral herpes), cold weather, hormonal changes such as menstruation, and physical trauma to the affected area. Recognizing your personal triggers can help you anticipate and sometimes prevent outbreaks.
Diet may also play a role. The amino acid arginine appears to support viral replication, and high arginine intake has been linked to reactivation in some cases. Foods particularly high in arginine include nuts, seeds, chocolate, and some grains. Citrulline, found in watermelon and some other foods, converts to arginine in the body and may have a similar effect. This doesn’t mean you need to eliminate these foods entirely, but being aware of heavy consumption during stressful periods may be worthwhile.
L-Lysine and Other Supplements
Lysine is the most widely discussed supplement for herpes management, and it does have some clinical evidence behind it. In a six-month double-blind trial, participants taking oral lysine averaged 2.4 times fewer outbreaks than the placebo group, with reduced symptom severity and shorter healing times. However, dosage matters significantly. A review of multiple studies found that doses under 1 gram per day were ineffective, while doses above 3 grams per day showed meaningful improvement in patients’ experience of the disease.
Lysine competes with arginine for absorption, which is thought to be its mechanism: by tipping the balance away from arginine, it may make the cellular environment less hospitable for viral replication. Propolis, a compound produced by bees, has also shown some promise in early studies for topical application during outbreaks. Neither of these replaces antiviral medication, but they may complement it.
Testing and Knowing Your Status
If you’re unsure whether you have HSV, blood tests can detect antibodies, but they have important limitations. After exposure, it can take up to 16 weeks for antibodies to reach detectable levels. Testing too soon can produce a false negative. False positives are also more common with herpes blood tests than with tests for infections like chlamydia or gonorrhea, particularly in people at low risk. A positive blood test in someone with no symptoms and no known exposure should be interpreted cautiously. Swab testing of an active sore is more reliable for confirming a diagnosis during an outbreak.
Gene Therapy Research
The closest thing to a potential cure is gene-editing research being conducted at Fred Hutchinson Cancer Center. The approach uses a specially engineered virus (a vector) to deliver molecular scissors called meganucleases directly to the nerve clusters where HSV hides. These enzymes cut the viral DNA in two places, damaging it beyond repair. The body’s own cellular cleanup systems then destroy the remnants.
In mouse studies, this therapy eliminated 90% of HSV-1 after oral infection and 97% after genital infection, with reductions continuing to improve over roughly a month. Viral shedding also dropped significantly in both frequency and amount. Earlier versions of the therapy required three vectors and two different enzymes; the latest version has been simplified to a single vector and one enzyme, which is an important step toward making it practical for human use.
This research is still preclinical, meaning it has not yet been tested in people. A therapeutic vaccine candidate from Moderna, called mRNA-1608, is in Phase 1/2 trials involving about 300 adults with recurrent genital HSV-2, with interim results being evaluated. Neither approach is available outside of research settings, and timelines for broader availability remain uncertain.
Living With HSV in Practical Terms
For most people, herpes becomes a manageable condition rather than a defining one. Initial outbreaks tend to be the most severe. Recurrences typically become less frequent and less intense over the years, especially with HSV-1 in the genital area. Many people eventually stop having noticeable outbreaks altogether, though the virus remains present.
The combination of daily suppressive antivirals, awareness of personal triggers, barrier protection, and open communication with partners represents the current best practice for minimizing both outbreaks and transmission risk. Adding lysine at effective doses (3 grams or more daily) is a reasonable supplement for those interested in additional management, though it shouldn’t replace antivirals if outbreaks are frequent or if reducing transmission is a priority.